Charles Schwab Investment Management Inc. Increases Position in Johnson & Johnson (NYSE:JNJ)

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Johnson & Johnson by 3.9% in the first quarter, owning approximately 18.9 million shares valued at over $3.1 billion.
• Analysts have mixed views on JNJ, with price targets ranging from $153.00 to $176.00, resulting in an overall rating of "Moderate Buy" with a consensus price target of $174.50.
• Johnson & Johnson declared a quarterly dividend of $1.30 per share, with a dividend yield of 3.0% and a payout ratio of 55.61%.

Charles Schwab Investment Management Inc. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,899,263 shares of the company's stock after acquiring an additional 712,181 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.79% of Johnson & Johnson worth $3,133,602,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Lantz Financial LLC grew its position in Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after buying an additional 377 shares during the period. Sulzberger Capital Advisors Inc. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $453,000. Joel Isaacson & Co. LLC increased its stake in shares of Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after buying an additional 2,526 shares during the last quarter. State of Wyoming increased its holdings in shares of Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company's stock valued at $1,487,000 after acquiring an additional 10,279 shares during the last quarter. Finally, Range Financial Group LLC grew its stake in Johnson & Johnson by 18.9% during the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after buying an additional 2,529 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

NYSE JNJ traded up $1.87 during mid-day trading on Friday, reaching $173.40. 7,686,049 shares of the stock were exchanged, compared to its average volume of 9,496,232. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $173.96. The company has a market capitalization of $417.61 billion, a P/E ratio of 18.55, a P/E/G ratio of 2.18 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The business's 50 day moving average is $158.89 and its 200-day moving average is $157.27.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the previous year, the firm earned $2.82 earnings per share. Johnson & Johnson's quarterly revenue was up 5.8% compared to the same quarter last year. On average, equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. Johnson & Johnson's payout ratio is presently 55.61%.

Wall Street Analyst Weigh In

JNJ has been the subject of several research analyst reports. Royal Bank Of Canada upped their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Barclays lifted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Finally, Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.